Also trades as: 0IIM.L (LSE) · $vol 0M
ESPR NASDAQ
Esperion Therapeutics, Inc.
1W: +15949.7%
1M: +1.3%
3M: +46.5%
YTD: -14.3%
1Y: +156.4%
3Y: +117.8%
5Y: -84.5%
$3.18
Last traded 2026-07-14 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
13 relationships13
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2021-04-26
Earliest Filing
2026-04-02
Latest Filing
partner: 7
investor: 4
target: 2
Counterparties (Filed by ESPR)
13 relationshipsCompanies named in ESPR's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Athyrium Opportunities IV Acquisition LP | — | investor | Purchased royalties and milestones receivables from the Company. | 2026-04-02 | View |
| Corstasis Therapeutics Inc. | — | target | Target company in the merger agreement with the Company. | 2026-04-02 | View |
| Otsuka Pharmaceutical Co., Ltd. | — | partner | Original licensee and collaborator in the License and Collaboration Agreement. | 2026-04-02 | View |
| Corstasis Therapeutics Inc. | — | target | Target company in a merger agreement where its assets will be merged into Esperion Therapeutics, Inc. | 2026-03-03 | View |
| OCM IP Healthcare Portfolio LP | — | investor | Purchased 100% of royalty interests on net sales of Bempedoic Acid in the DSE Territory for US$304,656,180. | 2024-06-28 | View |
| Daiichi Sankyo Europe GMBH | — | partner | Original licensor in the License and Collaboration Agreement governing the royalties sold to OCM IP Healthcare Portfolio | 2024-06-28 | View |
| Daiichi Sankyo Europe GmbH | — | partner | Settlement agreement and license amendment for commercial dispute resolution and territory rights | 2024-01-03 | View |
| Daiichi Sankyo Company Limited | — | partner | License amendment for exclusive rights in DS Territory including South Korea and Brazil | 2024-01-03 | View |
| Cantor Fitzgerald & Co. | — | partner | Sales agent for the 2023 Controlled Equity Offering | 2023-02-21 | View |
| Jefferies LLC | JEF | partner | Former sales agent for the 2021 Open Market Sale Agreement | 2023-02-21 | View |
| Daiichi Sankyo Company, Limited | — | partner | Entered into a License and Collaboration Agreement for exclusive development and commercialization rights in specific te | 2021-04-26 | View |
| Eiger III SA LLC | — | investor | Acted as purchaser agent for the Revenue Interest Purchase Agreement. | 2021-04-26 | View |
| Eiger Partners II LP | — | investor | Named as a purchaser in the Revenue Interest Purchase Agreement. | 2021-04-26 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-07-13 | Material Agreement; Termination of Agreement; Acquisition/Disposition; Financial Obligation; Delisti | Agreement Acquisition | View |
| 2026-07-08 | Shareholder Vote | View | |
| 2026-06-18 | Exhibits | View | |
| 2026-06-16 | Other Events | View | |
| 2026-06-09 | Other Events | View | |
| 2026-06-01 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-01 | Material Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-04-02 | Material Agreement; Acquisition/Disposition; Financial Obligation; Regulation FD; Exhibits | Agreement Acquisition | View |
| 2026-03-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-03-03 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2026-01-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-04 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-10-08 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-10-07 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-11 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-01 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-06-02 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR